Abstract 4737
Background
Malignant ependymomas are one of the main types of glioma that have high morbidity and mortality. The objective of this study was to construct, validate and calibrate novel nomograms for the survival of ME patients.
Methods
We utilized the Surveillance, Epidemiology, and End Results database (SEER) to retrieve patients with ME. We excluded patients with an unknown diagnosis, no follow up or with autopsy report only. Moreover, we utilized penalized regression models (PRM) by using “hdnom” package in R with the highest AUC and the most stable calibrations to build nomograms for overall (OS) and cancer-specific survival (CSS).
Results
Data of 3435 patients were retrieved and analyzed. We developed 18 PRM and chose Snet and SCAD for OS and CSS. These two models selected age, sex, year of diagnosis, marital status, site, race, type, surgery, radiation, and chemotherapy for the nomograms to be built. Our nomograms had stable calibrations with adequate to good accuracy AUC of 0.70 to 0.76 for the OS nomogram and AUC of 0.75 to 0.78 for the CSS nomogram.
Conclusions
In this population-based study, we developed nomograms that can better help physicians predict the prognosis and survival of ME patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sherief Ghozy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract